Marshall Appointed Chief Medical Officer of Caris Life Sciences

Article

John Marshall, MD, of Georgetown Lombardi and MedStar Georgetown University Hospital, has been appointed chief medical officer of Caris Life Sciences.

John Marshall, MD

John Marshall, MD

John Marshall, MD, of Georgetown Lombardi and MedStar Georgetown University Hospital, has been appointed chief medical officer of Caris Life Sciences.

Marshall has more than 20 years of experience as a medical oncologist and clinical trial investigator, most recently serving as associate director for Clinical Care at Georgetown Lombardi and the chief of the Division of Hematology-Oncology at MedStar Georgetown University Hospital. Marshall is also the founding director of Georgetown Lombardi's Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer.

"This is an exciting time because the precision oncology era has arrived and it is changing the cancer care landscape right now. I believe that molecular information captured from genomic and proteomic testing can dramatically improve our ability to treat patients smarter and ultimately improve outcomes," Marshall said. "I look forward to working more closely with the Caris Life Sciences team and broadening the availability of high quality, clinically useful tumor profiling services."

In his new role, Marshall will direct the Caris Life Science’s oncology research efforts through the Caris Research Institute and guide clinical strategies for innovative precision medicine tools and tumor profiling services, according to a news release from Caris Life Sciences. He will continue to serve as chairman of the Caris Centers of Excellence (COE) for Precision Medicine Network on behalf of Georgetown Lombardi Comprehensive Cancer Center.

A public/private collaboration, the COE Network includes 5 NCI-designated comprehensive cancer centers, and approximately 600 physicians across more than 150 locations. As part of the collaboration, network members are actively developing consensus guidelines for tumor profiling and precision medicine, while also participating in research and outcome-tracking initiatives for patients that have received tumor profiling.

"As a recognized global leader and GI cancer expert, and the founding Chairman of the Caris Centers of Excellence for Precision Medicine Network initiative, John has been a strong advocate and champion for the precision oncology movement. He brings deep clinical insights that will play a key role in our ability to fulfill the promise of precision medicine," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "We are very excited to welcome John to the Caris Life Sciences team and I look forward to working more closely with him and the leadership he will bring to the company."

Marshall has been the principal investigator for more than 150 clinical trials and is published in journals such as theJournal of Oncology, Clinical Colorectal Cancer, Gastrointestinal Cancer Researchand the Journal of Gastrointestinal Cancer. His numerous awards include being named the PER®Educator of the Year for 2016.

Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Related Content